February 19, 2019
Nativis Announces Additional Publication of Further Study in Patients with Recurrent Glioblastoma (rGBM)
Second Study Yields Additional Data Suggesting the Nativis Voyager® is Safe for Treatment of rGBM and the Potential Breadth of Technology Platform
SEATTLE (PRWEB) FEBRUARY 19, 2019
Nativis, Inc., (https://emulatetx.com) a clinical stage therapeutic device company developing non-invasive treatments for cancers and other serious diseases, today announced the publication of a second study (NAT-105), this one in Australia, of an early feasibility study in CNS Oncology suggesting that the Nativis Voyager device is safe for treatment of rGBM.
The Nativis Voyager produces ultra-low radio frequency energy (ulRFE®). The ulRFE cognate is created by measuring and recording the oscillating magnetic field produced by molecules in solution. The cognate is then used to produce a magnetic field using an electromagnetic coil worn externally on the head by the patient. This magnetic field is intended to induce a biologic response in solid tumors, such as rGBM.
The publication of this study, A Feasibility Study of the Nativis Voyager® Device in Patients with Recurrent Glioblastoma (rGBM) in Australia, may be viewed at https://www.futuremedicine.com/doi/full/10.2217/cns-2018-0017 or on the Nativis web site https://emulatetx.com/news/.
In the accompanying article Peek Behind the Paper, CNS Oncology staff interviewed Charles Cobbs, MD; Chair, Nativis Medical & Scientific Advisory Board; and Director of the Ben & Catherine Ivy Center for advanced Brain Tumor Treatment at Swedish Neuroscience Institute, Seattle. The interview gives Dr. Cobbs’s insight into the development of the Voyager system, its uses and clinical studies. The interview in its entirety may be read by going to https://www.neuro-central.com/2019/02/01/a-peek-behind-the-paper-charles-cobbs-on-the-nativis-voyager-for-the-treatment-of-glioblastoma/. Dr. Cobbs’ study may be viewed at https://www.futuremedicine.com/doi/10.2217/cns-2018-0013.
“We are excited to have this publication accepted by CNS Oncology in conjunction with our internationally recognized clinical trial partners, led by Anthony Dowling MD, St. Vincent Hospital, Australia,” stated Chris Rivera, Nativis Chief Executive Officer. “The data in this early feasibility study not only suggest that the Nativis Voyager device is safe for the treatment of rGBM, but add to our previous independent published study that also concluded that further studies to explore clinical utility are warranted.”
In conjunction with the publication of the studies, an accompanying editorial was authored by Victor Levin, MD, Founder of the Society of NeuroOncology, Emeritus Professor of Neuro-Oncology at The University of Texas, M.D. Anderson Cancer Center and Clinical Professor, Department of Neurosurgery, University of California San Francisco Medical School. The editorial may be viewed at https://www.futuremedicine.com/doi/10.2217/cns-2018-0019.
Rivera continued, “Unlike the previously published study, this study by Dr. Dowling and his team utilized the Voyager as a monotherapy in fifteen patients with rGBM, who were treated with one of two Voyager ulRFE cognates: one of which produces a magnetic field intended to produce mitotic inhibition, the other cognate producing a magnetic field intended to down-regulate PD-1 and CTLA-4. We are pleased that the data suggest that both cognates are safe for the treatment of rGBM and warrant further studies to explore clinical utility. We are excited by these data, which also demonstrate the potential impact of our platform ulRFE technology for our patients and their families.”
“Nativis is grateful to our clinical partners, patients, and their families in this effort to develop an effective treatment for one of the most difficult diseases to treat known to medical science.” Rivera went on to state, “Without the efforts of our dedicated and extraordinary clinical partners, our patients and their families would have fewer hopes to address the devastating effects of rGBM.”
About Nativis, Inc.
Founded in 2002 and headquartered in Seattle, WA, Nativis is a clinical-stage therapeutic device company. Nativis has invented and patented a groundbreaking technology that utilizes precisely targeted, ultra-low radio frequency energy (ulRFE) to specifically regulate metabolic pathways on the molecular and genetic levels – without chemicals, radiation or drugs – delivered via a simple-to-use non-invasive device called Nativis Voyager®. The company’s goal is to transform disease treatment on a global scale with ulRFE that can potentially be applied to a wide range of medical conditions, as well as to veterinary medicine and non-medical applications. Nativis’ initial focus is on the treatment of patients with brain cancer, who are not well served by conventional standard of care therapies, which often results in poor outcomes and devastating side effects. Additional pre-clinical work is focused on exploring new applications in other oncology settings and pain management. The Nativis Voyager system is an investigational medical device, limited by United States law to investigational use only.